Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Advertisement

European Commission Approves Povofortay (povorcitinib) for Adults with Moderate to Severe Hidradenitis Suppurativa – Incyte

Written by | 20 Nov 2026 | Dermatology

Incyte announced that the European Commission has approved Povofortay (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa.

“The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease. As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” – Bill Meury, Chief Executive Officer, Incyte.

The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.

Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and durable efficacy. Both studies met the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50, ≥50% reduction from baseline in the total abscess and inflammatory nodule count [AN count] without an increase in abscess or draining tunnel count relative to baseline) versus placebo at Week 12, at both studied doses (45 mg and 75 mg) in the overall intent-to-treat (ITT) population. Consistent efficacy was observed in the post-anti-TNF population, which is reflected in the EU indication, with a greater proportion of patients achieving HiSCR50 at Week 12 compared with placebo. Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Additionally, at Week 54, a high proportion of participants across both doses achieved clinically meaningful improvements in skin pain (40.5-46.8%), fatigue (49.0-58.0%) and skin condition-related (59.4-64.7%) and HS-specific (33.7-40.2%) quality of life (QoL).

The overall safety profile of Povofortay over 54 weeks was consistent with previously reported data; both doses were well tolerated, with no new or unexpected safety signals. The most frequent TEAEs across both studies and doses were acne, nasopharyngitis and upper respiratory tract infections with most events reported as mild or moderate.

“HS is a challenging disease to manage, and many patients struggle with the significant burden that affects many aspects of their lives. For clinicians, treatment goals need to go beyond controlling disease activity and also focus on what matters most to patients – genuine improvement in their daily life. This approval gives healthcare professionals and patients an important new option to consider when treating adults with moderate to severe HS, one that could help close the gap that exists in effectively managing this complex disease.” – Professor Dr. Falk Bechara, Ruhr University Bochum, Germany.

The U.S. Food and Drug Administration is currently reviewing Incyte’s New Drug Application (NDA) for povorcitinib as a treatment for moderate to severe HS. The application is supported by results from the STOP-HS1 and STOP-HS2 studies, with U.S. approval and launch anticipated in the first quarter of 2027.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.